CTCs and CECs as prognostic indicators in cancer
Medical Solutions™ has recently acquired all the elements of the CellSearch™
System (Immunicon Corp) for the enumeration of Circulating Tumour Cells (CTCs) and
Circulating Endothelial Cells (CECs) from human peripheral blood.
This exciting new development using the CellTracks® AutoPrep Station and the CellTracks®
Analyser II, (manufactured by Immunicon Corporation and supplied by Veridex LLC
in Europe), both complements and enhances Medical Solutions™ current reference
laboratory product portfolio.
The AutoPrep System fully automates and standardises the blood sample preparation
process whilst the unique cartridge format of the Analyser II makes fully quantifiable
CTC/CEC measurements possible.
CTCs
- The CellSearch™ Circulating Tumour Cell Kit is FDA approved for in vitro diagnostic
use
- The enumeration of CTCs in metastatic breast cancer is a proven prognostic indicator
- Can be used for many other epithelial origin carcinomas (e.g. colon and lung)
- A valuable tool for the monitoring of patient progress in clinical trials
- Can assist patient management in directing or re-directing therapeutic regimes
- Generates supportive data through the additional profiling of isolated cells
CECs
This platform technology can also be utilised to analyse circulating endothelial
cells (CEC's), important in vasculitis associated with cardiovascular, diabetes,
respiratory disease, as well as angiogenesis in cancer.
specialist profiling of isolated cells
Specialist staining can also be carried out on isolated cells. This includes HER2,
EGFR and other cell differentiation (CD) markers. Indeed any FITC labelled commercially
available antibody can be validated and utilised in parallel with the CellSearch™
System.
Progenitor cells may also be isolated for analysis.
Medical Solutions™ is the only UK commercial reference laboratory providing
CTC and CEC analysis.
recommended references:
Global Gene Expression Profiling of Circulating Tumor Cells
Circulating Tumor Cells in Patients with Breast Cancer Dormancy